Basic Ranexa Information

• INN (International Nonproprietary Name): Ranolazine
• Brand Names Available In United States: not specified
• ATC Code: C01EB18
• Forms & Dosages: ER tablet 375 mg; ER tablet 500 mg; ER tablet 750 mg; ER tablet 1000 mg (1000 mg is seldom available outside North America and Australia)
• Manufacturers In United States: Menarini International; Chiesi; Bausch Health; generics from Sandoz, Accord, Lek-Am
• Registration Status In United States: Prescription-only (Rx); FDA-approved for chronic stable angina under specialist supervision
• OTC / Rx Classification: Prescription-only (Rx)

Key Findings From Recent Trials

Major 2022–2026 Studies

Worried about what the latest studies say on ranolazine and whether it actually helps people with angina?

Recent randomized controlled trials and pooled analyses since 2022 emphasize ranolazine’s role as an add-on therapy for refractory chronic stable angina.

Large pragmatic RCTs compared ranolazine add-on therapy to optimized background antianginal regimens and focused on patient-centered endpoints.

These trials commonly enrolled patients with persistent angina despite beta-blockers, calcium channel blockers, or nitrates.

Meta-analyses pooled these trials to increase precision around symptom outcomes and safety signals.

Investigations since 2022 also explored arrhythmia-related endpoints, particularly atrial fibrillation, in exploratory substudies.

Trials used ranolazine extended-release tablets in commonly available strengths, titrated per labeling recommendations.

Main Outcomes

Is ranolazine likely to reduce how often angina attacks happen each week?

Across the largest trials, ranolazine produced modest but consistent reductions in weekly angina frequency compared with placebo or optimized background therapy.

Patients on ranolazine also showed reduced nitroglycerin rescue use in multiple studies.

Effect sizes are generally small to moderate in pooled analyses, with larger absolute benefit seen in patients intolerant of or not controlled by traditional agents.

Notably, ranolazine achieves symptom improvement without a significant reduction in heart rate, consistent with its neutral chronotropic profile.

Exploratory AF endpoints were inconsistent and have not produced definitive evidence to support routine use for AF prevention.

Safety Observations

Are there safety issues to watch for if a clinician prescribes ranolazine?

The principal safety signal across recent studies is dose-dependent QT prolongation, especially with doses exceeding 1000 mg twice daily or in patients with hepatic or renal impairment.

Serious arrhythmias are rare in trial populations but have been reported in cohorts taking interacting drugs that raise ranolazine exposure.

Studies consistently flagged the need for baseline ECGs and caution when combining ranolazine with other QT-prolonging agents.

Regulatory labels continue to list chronic stable angina as the primary approved indication, and recent trial findings align with agency guidance.

Clinical Mechanism Of Action

Layman’s Explanation

Want to know in plain terms how ranolazine helps chest pain without changing your pulse?

Ranolazine improves how the heart muscle uses energy during low-oxygen periods, which eases chest pain without lowering heart rate or blood pressure.

That neutral effect on heart rate makes it a useful add-on when beta-blockers or nitrates are not tolerated or not sufficient.

Scientific Breakdown

How does ranolazine work at the cellular level?

Ranolazine selectively inhibits the late inward sodium current (late INa) in ischemic cardiomyocytes.

By decreasing late INa, ranolazine reduces intracellular sodium overload and limits secondary calcium accumulation through the Na+/Ca2+ exchanger.

Less intracellular calcium lowers diastolic wall tension, improves myocardial relaxation, and can enhance subendocardial perfusion.

Pharmacokinetically, ranolazine is formulated as extended-release (ER) tablets in strengths that support twice-daily dosing.

Metabolism occurs primarily via CYP3A with a minor role for CYP2D6, creating interaction risks with strong CYP3A inhibitors and inducers.

QT effects are dose-dependent and relate to mild hERG blockade observed in mechanistic studies.

Mechanistic data support clinical use for chronic stable angina consistent with regulatory labeling.

Scope Of Approved & Off-Label Use

United States Approvals

Wondering what ranolazine is officially approved to treat in the United States?

Ranolazine (brand name Ranexa in many markets) is approved by regulatory agencies including the FDA for chronic stable angina as adjunctive therapy when symptoms persist despite standard treatment.

Label dosing typically starts at 500 mg extended-release twice daily with titration to 1000 mg twice daily as tolerated.

The maximum recommended total daily dose is 2000 mg per product information.

Notable Off-Label Trends

Curious whether ranolazine is being used for anything beyond angina?

Investigational off-label uses include atrial fibrillation suppression and postoperative AF prevention, but current data are mixed and remain exploratory.

Small trials and observational series have suggested possible AF burden reduction in selected patients, but this evidence is insufficient for regulatory endorsement.

Other exploratory areas include symptomatic microvascular angina and heart failure with preserved ejection fraction for diastolic symptom modulation.

In clinical practice, U.S. prescribers generally reserve ranolazine for patients intolerant of or insufficiently controlled on nitrates, calcium channel blockers, or beta-blockers.

Dosage Strategy

General Dosing

How should ranolazine usually be started and adjusted?

Standard initiation is ranolazine ER 500 mg twice daily, increased to 1000 mg twice daily based on efficacy and tolerability.

Do not exceed a total daily dose of 2000 mg per product information and regulatory guidance.

Available ER tablet strengths include 375 mg, 500 mg, 750 mg and, in some markets, 1000 mg.

Tablets may be taken with or without food, and keeping timing consistent helps tolerability.

Condition-Specific Dosing

What dose is recommended for a patient with chronic stable angina?

Adults with chronic stable angina should start at 500 mg ER twice daily and may be titrated to 1000 mg ER twice daily for persistent symptoms.

Renal impairment requires caution with dose adjustments for moderate disease and avoidance in severe renal dysfunction due to elevated exposure and QT risk.

Severe hepatic impairment is a contraindication, and dose reduction or avoidance is advised for moderate hepatic impairment.

Elderly patients, especially those older than 75 years, should be monitored closely for QT effects and adverse events and often start low.

Pediatric use is not approved and safety has not been established.

Ranolazine is commonly combined with beta-blockers, calcium channel blockers, nitrates, or ACE inhibitors, provided interaction checks are performed.

Safety Protocols

Contraindications

Who should definitely not take ranolazine?

Absolute contraindications include known hypersensitivity to ranolazine, severe hepatic impairment, and concomitant use with strong CYP3A inhibitors such as ketoconazole or clarithromycin.

Ranolazine should not be used in patients with existing clinically significant QT prolongation or congenital long QT syndromes.

Adverse Effects

What side effects do patients commonly report on ranolazine?

Common adverse effects include constipation, nausea, headache, and dizziness.

Less common but clinically important effects include palpitations, elevated blood pressure, syncope, and dose-dependent QT interval prolongation.

Serious arrhythmias are uncommon in trials but are more likely when ranolazine exposure increases due to drug interactions or organ impairment.

Monitoring recommendations include a baseline ECG in patients with QT risk factors and periodic ECGs if the dose is escalated or interacting drugs are added.

Clinicians should monitor liver function and renal function as clinically indicated.

Patients should be counseled to report fainting, severe dizziness, or new palpitations promptly.

Interaction Mapping

Food Interactions

Are there foods or drinks that change how ranolazine works?

Ranolazine ER tablets can be taken with or without food, and keeping dosing relative to meals consistent helps tolerability.

Avoid grapefruit and grapefruit juice because they can inhibit CYP3A and increase ranolazine plasma levels and the risk of QT prolongation.

Drug Combinations To Avoid

Which medicines should never be combined with ranolazine?

Concomitant use with strong CYP3A inhibitors (for example, ketoconazole and clarithromycin) is contraindicated because they markedly increase ranolazine exposure.

Strong CYP3A inducers such as rifampin or carbamazepine can reduce ranolazine levels and clinical effect.

Caution is required with other QT-prolonging agents, including certain antiarrhythmics and antipsychotics, due to additive QT risk.

Moderate CYP3A inhibitors may require dose adjustment or avoidance, and clinicians should review all prescription, OTC, and supplement use before starting ranolazine.

Patient Experience Analysis

Survey Data

Do real patients say ranolazine helps their angina?

Real-world surveys report improved angina frequency and reduced nitroglycerin rescue use among many patients prescribed ranolazine ER.

Benefit is most apparent in patients with refractory symptoms or intolerance to beta-blockers and nitrates.

Adherence is influenced by gastrointestinal side effects such as constipation and nausea and by the twice-daily dosing schedule.

Elderly patients commonly undergo cautious titration and show higher discontinuation rates due to side effects or polypharmacy concerns.

Forum Trends

What do patient forums and social media say about ranolazine?

Forum posts are mixed, with some users praising symptom control and minimal heart-rate effects and others reporting bothersome constipation or dizziness leading to stopping the medication.

Common consumer complaints include variability in strength availability and cost at U.S. pharmacies.

Clinicians who monitor forums often advise ECG follow-up and thorough medication interaction checks for patients considering ranolazine.

Distribution & Pricing Landscape

Global Distribution

Where is ranolazine sold and under what strengths?

Ranolazine is marketed internationally as Ranexa and under various generics, with ER tablets commonly available in 375 mg, 500 mg and 750 mg strengths and 1000 mg tablets in some markets such as Canada and Australia.

Primary manufacturers include Menarini International, Chiesi, Bausch Health, and region-specific generic suppliers such as Accord, Sandoz, and Lek‑Am.

Ranolazine is prescription-only across the major regulatory regions.

US Pricing And Access

How easy is it for U.S. patients to access ranolazine and what does it cost?

In the United States, brand Ranexa pricing can be substantial compared with generic alternatives where generics are available.

Insurance coverage and formulary placement vary, and prior authorization for branded Ranexa is common when less costly substitutes exist.

Periodic shortages or discontinuations of certain strengths, such as 500 mg, have been reported and can affect switching and prescribing.

In our online pharmacy, ranexa is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

Which other drugs are typically used for chronic stable angina?

Alternatives include long-acting nitrates (isosorbide mononitrate/dinitrate), beta‑blockers (metoprolol, bisoprolol), calcium channel blockers (amlodipine, diltiazem), and ivabradine for heart-rate control in selected patients.

Choice of therapy depends on comorbidities, hemodynamics, prior tolerability, and drug–drug interaction potential.

Pros And Cons

What are the advantages and disadvantages of ranolazine compared with other antianginal drugs?

Ranolazine Pros: provides symptomatic benefit as add-on therapy; neutral effect on heart rate and blood pressure; convenient ER twice-daily dosing.

Ranolazine Cons: dose-dependent QT prolongation risk; CYP3A interaction potential; common GI side effects; higher cost or availability problems in some markets.

Beta-Blocker Pros: mortality benefit after myocardial infarction and effective rate control.

Beta-Blocker Cons: may cause bradycardia, bronchospasm, and fatigue.

Calcium Channel Blocker Pros: good vasodilatory symptom relief and helpful when beta-blockers are contraindicated.

Calcium Channel Blocker Cons: risk of edema, hypotension, and drug interactions.

Nitrate Pros: rapid symptomatic relief for acute episodes.

Nitrate Cons: tolerance with continuous use and side effects such as headache and hypotension.

Regulatory Status

Approved Indications And Status

Is ranolazine formally approved for angina around the world?

Regulatory agencies including the FDA, EMA, Health Canada, and TGA approve ranolazine for chronic stable angina as a prescription-only medication used under specialist supervision.

Product labeling provides guidance on dosing, contraindications such as severe hepatic impairment and use with strong CYP3A inhibitors, and the need for QT monitoring in at‑risk patients.

Regional Availability

Are there differences in available tablet strengths by country?

ER 375–750 mg strengths are commonly marketed worldwide, while 1000 mg tablets are primarily available in Canada and Australia and are less common elsewhere.

Patent expirations have enabled generics in several regions, changing pricing and formulary positions in some markets.

Regulatory guidance currently discourages off-label use for atrial fibrillation outside clinical trials.

Consolidated FAQ

Quick Answers Clinicians & Patients Need

What is Ranexa?

Ranexa is a common brand name for ranolazine, an extended-release antianginal approved for chronic stable angina.

How is it dosed?

Start ranolazine ER 500 mg twice daily and consider titration to 1000 mg twice daily; do not exceed 2000 mg per day.

What are the major safety concerns?

Key safety concerns include dose-dependent QT prolongation and interactions with strong CYP3A inhibitors, and the drug is contraindicated in severe hepatic impairment.

Can ranolazine be used with beta-blockers?

Yes, it is commonly used as add-on therapy with beta-blockers, but interaction and QT risk assessments are necessary.

Is Ranexa available as a generic?

Generics are available in several regions and availability varies by country and pharmacy.

What are common off-label uses?

Investigational off-label uses include atrial fibrillation and HFpEF, but these are not approved indications.

What should a patient do for a missed dose?

Take the next scheduled dose and do not double up on doses.

Visual Guide

Suggested Visual Elements For Blog Or Patient Leaflets

Want visuals that help patients understand ranolazine quickly?

Create a simple mechanism infographic showing late INa inhibition leading to reduced intracellular Ca2+ and improved diastolic tension.

Use a dosing flowchart that starts at 500 mg BID, shows reassessment at 2–4 weeks, and indicates titration to 1000 mg BID if needed with flags for renal and hepatic caution.

Design a safety checklist graphic that lists baseline ECG, medication review for CYP3A inhibitors, and LFT/renal checks.

Include a global packaging map highlighting common strengths (375/500/750 mg and 1000 mg in Canada/Australia).

Data To Highlight

What clinical data points matter most for quick reference?

Include an evidence summary box with symptom reduction effect sizes from meta-analyses and patient-reported improvement in weekly angina and nitroglycerin use.

Highlight main adverse events such as constipation and QT prolongation.

Always cite sources such as product labels and regulatory agencies on visuals to support E‑E‑A‑T.

Storage & Transport

Storage Recommendations

How should ranolazine be stored at the pharmacy and at home?

Store ranolazine ER tablets at controlled room temperature, 20–25°C (68–77°F), in a dry place protected from moisture, heat, and direct light.

Keep medications out of reach of children and in original packaging where possible.

Transport Considerations

Are there special shipping needs for ranolazine?

Cold-chain transport is not required, but tablets should be protected from humidity and temperature extremes during shipping.

Pharmacies should rotate stock by expiry date and monitor supply notices for strength-specific shortages.

Maintain batch traceability for recalls and align local packaging language with country requirements when distributing internationally.

Guidelines For Proper Use

Clinician Checklist

What steps should clinicians follow when starting ranolazine?

Confirm indication as chronic stable angina refractory or intolerant to first-line therapy.

Obtain baseline ECG to assess QTc, check LFTs and renal function, and review all medications for CYP3A interactions.

Initiate ranolazine ER 500 mg twice daily and reassess symptoms and ECG in 1–4 weeks.

Titrate to 1000 mg twice daily if needed and tolerated.

Avoid in severe hepatic impairment and with strong CYP3A inhibitors, and modify dosing for moderate organ impairment.

Document informed consent for any off-label use and consider cardiology referral for complex cases.

Patient Counseling Points

What should patients know before they start ranolazine?

Take ER tablets consistently twice daily and do not crush or chew the tablets.

Report palpitations, fainting, severe dizziness, or syncope immediately.

Avoid grapefruit and grapefruit juice while taking ranolazine.

Emphasize adherence, the monitoring plan including ECG follow-ups, and common side effects such as constipation and nausea.

Provide practical information on cost, availability, and alternatives in case of supply issues.

Consolidated Delivery Across United States

Concluding Notes

What is the bottom line clinicians and patients should take from this summary?

Ranolazine is an evidence-supported adjunct for chronic stable angina with modest symptom benefits and a neutral effect on heart rate.

The major safety consideration is dose-dependent QT prolongation, especially in the setting of hepatic or renal impairment or with interacting drugs that increase exposure.

Regulatory approval is focused on chronic stable angina, and off-label uses remain investigational.

Clinicians should perform baseline ECGs, review medication lists for CYP3A interactions, and monitor renal and hepatic function as appropriate.

Patients should be counseled on adherence, dosing, side effects, and the need to avoid grapefruit juice.

For access, ask the pharmacy about brand versus generic availability, formulary placement, and potential prior authorization requirements.

Clinical decisions should always align with product labeling and specialist guidance when needed.